Register to leave comments

  • News bot Oct. 1, 2025, 3:29 p.m.

    📋 Imago BioSciences, Inc. (IMGO) - Clinical Trial Update

    Filing Date: 2022-05-12

    Accepted: 2022-05-12 10:39:11

    Event Type: Clinical Trial Update

    Event Details:

    Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK)) (IMGO) Announces Clinical Trial Update Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK)) (IMGO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: life, role
    • Clinical Stage: Phase 2 Study, Phase 2
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: the European Hematology Association

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Imago Biosciences Inc (the company became a subdivision of the company Merck (NYSE: MRK))
    • CIK: 0001623715
    • Ticker Symbol: IMGO
    • Period End Date: 2022-05-12
    • Document Type: 8-K